Since 2017, two newer VMAT2 inhibitors have been approved by the FDA for managing some hyperkinetic movement disorders such as chorea (especially in patients with HD) and tics (especially in those suffering from TS) (8, 19, 20). This evidence concerns the gene SLC18A2 and Chorea.